Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2022 on August 25, 2022, at 10.00. The report will be published on August 25, 2022, at 07.45 am CEST, and will be available together with presentation images on raysearchlabs.com.
Johan Löf, founder and CEO, and Björn Hårdemark, interim CFO, will present the company's development in a webcast. After the presentation (held in English) there is the opportunity to ask questions.
Link to webcast: https://raysearchlabs.creo.se/220825
Or dial in to join the webcast:
Sweden: + 46 (0) 8 505 100 31
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Björn Hårdemark, interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 709 564 217